Panacea Biotec Limited — Board Meeting, 30-05-2025: Outcome of Board Meeting

Panacea Biotec Ltd has announced a board meeting to approve the financial results for the quarter and half-year. Consolidated numbers show a net loss after tax of ₹8.72 crore, widening from ₹1.50 crore last year, with total income steady at around ₹559 crore. The vaccine segment struggled with a loss before tax of ₹16.52 crore, while formulations posted a profit of ₹8.57 crore. No dividend was declared due to losses. The board also approved appointing M/s R & D Company Secretaries as Secretarial Auditors for five years, pending shareholder approval.